Epics Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Epics Therapeutics General Information
Description
Operator of a drug discovery and development company intended to invent and develop small molecule drugs targeting ribonucleic acid (RNA) epigenetic mechanisms. The company drugs are developed by acid modifications, epigenomics, and transcriptomics, enabling medical practitioners to provide life-changing therapies for cancer patients.
Contact Information
Website
www.epicstherapeutics.comCorporate Office
- 47 Rue Adrienne Bolland
- 6041 Gosselies
- Belgium
Corporate Office
- 47 Rue Adrienne Bolland
- 6041 Gosselies
- Belgium
Epics Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-Apr-2026 | Completed | Clinical Trials - Phase 2 | |||
| 7. Early Stage VC | 28-Apr-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Early Stage VC | 01-Mar-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Secondary Transaction - Private | 01-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series A) | 04-Mar-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Seed Round | 01-Apr-2018 | Completed | Clinical Trials - Phase 2 | |||
| 2. Accelerator/Incubator | 01-Jan-2018 | Completed | Clinical Trials - Phase 2 | |||
| 1. University Spin-Out | 01-Jan-2018 | Completed | Clinical Trials - Phase 2 |
Epics Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Preference Shares | ||||||||
| Preference Shares | 60,638 | $84.84 | $84.84 | 1x | $84.84 | 12.96% | ||
| Ordinary | 56,304 | $70.7 | $70.7 | 1x | $70.7 | 12.04% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Epics Therapeutics Comparisons
Industry
Financing
Details
Epics Therapeutics Competitors (1)
One of Epics Therapeutics’s competitors is DESTINA, a Formerly VC-backed company based in Granada, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DESTINA | Formerly VC-backed | Granada, Spain |
Epics Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Epics Therapeutics Patents
Epics Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195795-A1 | Synthesis of ( r)- n-(cyclopropylmethyl)-1-(6-(3-(5-(5-cyclopropylpyridin-3-yl)-1,3,4-thiadiazol-2-yl)oxetan-3-yl)pyridin-3-yl)piperidin-3-amine | Pending | 19-Mar-2025 | ||
| WO-2026167147-A1 | Heteroaryl carboxylic acid derivatives as gpr84 agonists | Pending | 06-Feb-2025 | ||
| WO-2026017844-A1 | Combination therapies comprising a mettl3 inhibitor and a bcl2 inhibitor | Pending | 19-Jul-2024 | ||
| WO-2026017846-A1 | Piperidine derivatives as mettl3 inhibitors for the treatment of carcinomas | Pending | 19-Jul-2024 | ||
| AU-2024210234-A1 | Piperidine derivatives as mettl3 inhibitors | Pending | 20-Jan-2023 | C07D401/14 |
Epics Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Epics Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Equidis Ventures | Venture Capital | Minority | ||
| Fund+ | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Société Fédérale de Participations et d'Investissement | Holding Company | Minority | ||
| BNP Paribas Fortis Private Equity | Growth/Expansion | Minority |
Epics Therapeutics FAQs
-
When was Epics Therapeutics founded?
Epics Therapeutics was founded in 2018.
-
Where is Epics Therapeutics headquartered?
Epics Therapeutics is headquartered in Gosselies, Belgium.
-
What is the size of Epics Therapeutics?
Epics Therapeutics has 30 total employees.
-
What industry is Epics Therapeutics in?
Epics Therapeutics’s primary industry is Drug Discovery.
-
Is Epics Therapeutics a private or public company?
Epics Therapeutics is a Private company.
-
What is Epics Therapeutics’s current revenue?
The current revenue for Epics Therapeutics is .
-
How much funding has Epics Therapeutics raised over time?
Epics Therapeutics has raised $38.9M.
-
Who are Epics Therapeutics’s investors?
Equidis Ventures, Fund+, , Société Fédérale de Participations et d'Investissement, and BNP Paribas Fortis Private Equity are 5 of 7 investors who have invested in Epics Therapeutics.
-
Who are Epics Therapeutics’s competitors?
DESTINA is a competitor of Epics Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
